Bayer, which employs 100,000 people, clearly had a bad year in 2023, with flagship products selling poorly and new drugs performing less well than announced. As a result, the company’s financial results were down and its share price fell sharply. Bill Anderson, former head of Roche’s pharmaceuticals division, who took over as Bayer’s CEO in June 2023, not only finds this performance “unacceptable” but also believes it is the result of bureaucratic red tape, a lack of creativity and a lack of en
…
As a Berlin correspondent for the French and Swiss press since the late 1990s, I cover a wide range of economic, political and social issues, with a particular focus on the German business and labour market. My areas of interest include co-determination, digitalisation, demographics and ESG/DEI policies.